MeVis Medical Solutions AGXETR: M3V

MeVis Medical Solutions AG: Forecast Adjustment for Fiscal Year 2025/2026

· Issued by MeVis Medical Solutions AG

Summary by 6ix AI

MeVis Medical Solutions AG, a Bremen-based software company in image-based medicine, revised its forecast for fiscal year 2025/2026 on September 28, 2026, based on preliminary results, saying management now expects the company will not meet its financial targets.

Key details

  • Revenue for fiscal year 2025/2026 is now expected to decline year-over-year to a range of €15.0 million to €15.5 million, down from the previous forecast of €16.5 million to €17.0 million.
  • EBIT (earnings before interest and taxes) for fiscal year 2025/2026 is now expected to be negative, in a range of € -1.0 million to € -1.5 million, compared with the previous forecast of € 0.5 million to € 1.0 million.
  • The company gives the reasons as lower revenue due to subdued demand in the mammography sector for the customer Hologic and the persistently slow rollout of lung cancer screening in Germany.

What’s still pending

  • The new forecast is based on preliminary figures and management's current assessment.
  • The EBIT forecast assumes a stable exchange rate of 1.16 USD/EUR.

6ix AI wrote this summary from the release below and checked it against the release.

EQS-Ad-hoc: MeVis Medical Solutions AG / Key word(s): Forecast / Full year
MeVis Medical Solutions AG: Forecast Adjustment for Fiscal Year 2025/2026

28-Sep-2026 / 17:53 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.


Bremen, September 28, 2026 – MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading software company in the field of image-based medicine, is revising its forecast for the current fiscal year based on preliminary results.

According to the management’s current assessment, the company will not meet its financial targets. The reasons for this continue to be lower revenue due to subdued demand in the mammography sector for the customer Hologic and the persistently slow rollout of lung cancer screening in Germany.

Based on preliminary figures, management now expects revenue for the 2025/2026 fiscal year to decline year-over-year to a range of €15.0 million to €15.5 million (previous forecast: €16.5 million to €17.0 million). Consequently, the company expects negative earnings before interest and taxes (EBIT) for the 2025/2026 fiscal year in the range of € -1.0 million to € -1.5 million (previous forecast: € 0.5 million to € 1.0 million), assuming a stable exchange rate of 1.16 USD/EUR.

************************************************************************

Contact:

Kirchhoff, Marcus / CEO
End of Inside Information

28-Sep-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language:English
Company:MeVis Medical Solutions AG
Caroline-Herschel-Str. 1
28359 Bremen
Germany
Phone:+49 421 224 95 0
Fax:+49 421 224 95 999
E-mail:[email protected]
Internet:http://www.mevis.de
ISIN:DE000A0LBFE4
WKN:A0LBFE
Listed:Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX
LEI Code:529900Z8B6L1WCLNHW14
EQS News ID:2406544
End of AnnouncementEQS News Service

2406544  28-Sep-2026 CET/CEST

MeVis Medical Solutions AG on 6ix

Story so far

Earlier from MeVis Medical Solutions

All MeVis Medical Solutions news releases